4 results about "Glycated hemoglobin" patented technology

This invention provides a hypoglycemic subspecies of Bifidobacterium animalis (Liver) and its applications. The Bifidobacterium animalis (Liver) subspecies is named Tianshan-1 and is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35821 on September 5, 2025. Cell experiments show that Tianshan-1 significantly promotes the secretion of GLP-1 from human colorectal adenocarcinoma cells NCI-H716 and upregulates GCG gene expression levels. Animal experiments confirm that this strain significantly increases serum GLP-1 concentration in diabetic mice and reduces fasting blood glucose and glycated hemoglobin levels, with no significant difference in hypoglycemic effect compared to the positive control. This strain is a food-grade safe probiotic with a clear mechanism of action and stable effects, providing a safe, long-lasting, and industrially viable new probiotic resource for diabetes prevention and treatment, with broad application prospects.

Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.

The present invention pertains to the field of medical technology, specifically disclosing the pharmaceutical application of dimyricetin-based diselenide in type II diabetes. After four weeks of continuous administration, compared with the model control group, the test substances DMS-ASD and AQ-C-a demonstrated effects that were basically equivalent to the positive control drug, semaglutide injection, in reducing fasting blood glucose levels after 16 hours of fasting in db / db mice, reducing random blood glucose levels in db / db mice, inhibiting postprandial blood glucose elevations in db / db mice, decreasing the HbA1c content of glycated hemoglobin in db / db mice, and influencing body weight and food intake in db / db mice. The pharmaceutical application of dimyricetin-based diselenide in type II diabetes holds great promise.